分子对接与代谢组学解析原花青素抗白念珠菌生物膜机制
研究以ALS3为靶点虚拟筛选抗白念珠菌生物膜配体,并探究原花青素(PAC)的抗菌与抗生物膜活性及代谢组学机制。结果显示PAC对白念珠菌MIC为256 μg/ml、MFC为1 024 μg/ml,呈时间剂量依赖性;1 024 μg/ml可抑制80%生物膜形成并对40%成熟生物膜有分散作用;代谢组学提示其机制涉及能量代谢、核酸合成、膜结构破坏及氧化应激。
要点
- PAC对白念珠菌MIC为256 μg/ml,MFC为1 024 μg/ml,呈时间剂量依赖性。
- PAC 1 024 μg/ml抑制80%生物膜形成,对40%成熟生物膜有分散作用。
- PAC抗生物膜机制与能量代谢、核酸合成障碍、膜破坏及氧化应激相关。
核心结论
- 以ALS3为靶点虚拟筛选抗白念珠菌生物膜苗头化合物具有可行性。
- PAC为白念珠菌ALS3靶点抑制剂,其抗生物膜机制涉及能量代谢、核酸合成障碍、膜结构破坏及氧化应激加剧。
研究设计与样本
- 2023年1—12月在贵阳市妇幼保健院检验科开展研究。
- 采用分子对接虚拟筛选从待选药物库中筛选ALS3潜在配体。
- 通过微量液基稀释法测定PAC对白念珠菌的MIC和MFC并绘制时间-生长曲线。
- 采用二甲氧唑黄(XTT)染色法探究PAC对白念珠菌生物膜形成及24 h成熟生物膜的弥散作用。
- 采用液相色谱-质谱联用技术鉴定PAC作用后的白念珠菌代谢产物,运用主成分分析、偏最小二乘法判别分析和t检验筛选差异代谢物。
主要发现
- 通过Glide三级筛选(SP、XP、HTVS)共得到69个化合物,根据对接打分优于地西泮且排除抗生素,获得打分优秀且结合模式可观的化合物PAC。
- PAC的MIC为256 μg/ml,MFC为1 024 μg/ml,呈时间剂量依赖性。
- PAC对白念珠菌生物膜50%抑制率的浓度为256 μg/ml(单因素方差分析,F=15.92,P<0.001)。
- PAC浓度达1 024 μg/ml时可抑制80%白念珠菌生物膜形成(单因素方差分析,F=15.92,P<0.001)。
- 对已形成成熟生物膜的白念珠菌,PAC浓度达1 024 μg/ml时对40%成熟生物膜具有分散作用(单因素方差分析,F=5.01,P=0.002)。
关键数值与推荐
- PAC对白念珠菌MIC为256 μg/ml,MFC为1 024 μg/ml。
- PAC对生物膜50%抑制率为256 μg/ml(F=15.92,P<0.001),80%抑制率为1 024 μg/ml(F=15.92,P<0.001)。
- PAC对成熟生物膜40%分散作用的浓度为1 024 μg/ml(F=5.01,P=0.002)。
- 非靶向代谢组学显示PAC作用后白念珠菌差异代谢物总数350个,其中119个上调、231个下调。
- 显著变化的差异代谢物包括5-羟基哌啶甲酸、罗丹明123、尿囊素、吲哚丁酸、硫胺素等;主要富集通路为碳水化合物代谢、膜转运系统、脂质代谢、辅因子与维生素代谢、核苷酸代谢、氨基酸代谢。
临床怎么用
- PAC可作为靶向ALS3抑制白念珠菌生物膜形成的候选化合物。
- PAC对成熟生物膜具有分散作用,提示其可能用于生物膜相关感染的辅助干预。
- 代谢组学结果提示PAC抗生物膜机制涉及能量代谢、核酸合成、膜结构及氧化应激等多通路。
局限性
- 原文未报告体内实验、临床样本或安全性评价数据。
- 原文未报告PAC对宿主细胞毒性及耐药性诱导的相关结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To screen out potential ligands of Agglutinin-like sequence protein 3 (ALS3) with anti-adhesion from the candidate drug library. To clarify the antibacterial and anti-biofilm activities of proanthocyanidins (PAC) and conduct a preliminary exploration of their metabolomics mechanisms. From January to December in 2023, at the Laboratory Department of Guiyang Maternal and Child Health Hospital,using ALS3 as the target protein, the molecular docking virtual screening method was adopted to screen out ALS3 inhibitors with potential resistance to biofilm formation. The minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of PAC for Candida albicans were determined by the micro-liquid-based dilution method, and the time-growth curve was plotted to explore the antibacterial activity of PAC for Candida albicans. The XTT[2, 3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] staining method was used to explore the formation of Candida albicans biofilms by PAC and its dispersal effect on the formation of mature biofilms within 24 hours. The metabolites of Candida albicans after the action of PAC were identified by liquid chromatography-mass spectrometry. Multivariate analysis (principal component analysis and partial least squares discriminant analysis) and univariate analysis (t-test) were used to screen differential metabolites to preliminarily explore the anti-biofilm mechanism of PAC. The results showed that a total of 69 compounds were obtained through Glide's three-level screening (SP, XP, HTVS). Based on the criteria of (1) docking scores better than diazepam and (2) excluding antibiotics, PAC compounds with excellent scores and relatively promising pattern binding were obtained. The MIC of PAC is 256 μg/ml, and the MFC is 1 024 μg/ml, showing a time-dose dependence. The concentration of PAC with a 50% inhibition rate on Candida albicans biofilm is 256 μg/ml(one-way analysis of variance, F=15.92,P<0.001). When the concentration reaches 1 024 μg/ml, PAC can inhibit 80% of Candida albicans biofilm formation(One-way analysis of variance, F=15.92,P<0.001).For mature Candida albicans biofilms, when the PAC concentration reaches 1 024 μg/ml, it exhibits a dispersal effect on approximately 40% of the biofilm.(One-way analysis of variance, F=5.01,P=0.002). The results of non-targeted metabolomics indicated that compared with the untreated control group, the total number of differential metabolites of Candida albicans under the action of PAC was 350, among which 119 were up-regulated and 231 were down-regulated. The significantly changed differential metabolites include: 5-hydroxypiperidinic acid, Rhodamine 123, allantoin, indolebutyric acid, thiamine, etc.The main metabolic pathways enriched by differential metabolites are: global and overview maps, carbohydrate metabolism, membrane transport systems, lipid metabolism, cofactor and vitamin metabolism, nucleotide metabolism, and amino acid metabolism. In conclusion,it is feasible to use ALS3 as the target and a virtual screening method to search for the hit compounds of anti-Candida albicans biofilms. PAC was revealed to be an inhibitor targeting ALS3 in Candida albicans, and its anti-biofilm mechanism is associated with disturbances in energy metabolism, nucleic acid synthesis, membrane structure disruption, and enhanced oxidative stress. 本研究从待选药物库中筛选出具有抗黏附的凝集素样序列蛋白3(ALS3)的潜在配体;明确原花青素(PAC)抗菌活性和抗生物膜活性,并对其代谢组学机制进行初步探讨。2023年1—12月在贵阳市妇幼保健院检验科,采用分子对接虚拟筛选的方法筛选出对生物膜形成有潜在抵抗作用ALS3抑制剂;通过微量液基稀释法测定PAC对白念珠菌最低抑菌浓度(MIC)和最小杀菌浓度(MFC),并绘制时间-生长曲线(GC),探究PAC对白念珠菌的抗菌活性;采用二甲氧唑黄染色法探索PAC对白念珠菌生物膜形成及对24 h形成成熟生物膜的弥散作用;采用液相色谱-质谱联用技术对PAC作用后的白念珠菌的代谢产物进行鉴定,运用多变量分析(主成分分析和偏最小二乘法判别分析)和单变量分析(t检验),筛选差异代谢物以初步探究PAC的抗生物膜机制。结果显示,通过对Glide三级筛选(SP,XP,HTVS)能得到共69个化合物,根据(1)对接打分优于地西泮;(2)抗生素除外,获得打分优秀且模式结合较为可观的化合物PAC。PAC的MIC为256 μg/ml,MFC为1 024 μg/ml,呈时间剂量依赖性。PAC对白念珠菌生物膜50%抑制率的浓度为256 μg/ml(单因素方差分析,F=15.92,P<0.001),当浓度达到1 024 μg/ml时PAC可抑制白念珠菌80%生物膜形成(单因素方差分析,F=15.92,P<0.001)。对已形成成熟生物膜的白念珠菌,PAC浓度达到1 024 μg/ml时,对40%成熟生物膜具有分散作用(单因素方差分析,F=5.01,P=0.002);非靶向代谢组学结果表明,PAC作用下的白念珠菌与未加处理对照组比较,差异代谢物总数350个,其中119个上调,231个下调。显著变化的差异代谢物包括:5-羟基哌啶甲酸,罗丹明123,尿囊素,吲哚丁酸,硫胺素等。差异性代谢物主要富集的代谢通路为:碳水化合物代谢,膜转运系统,脂质代谢,辅因子与维生素代谢,核苷酸代谢,氨基酸代谢。综上,以ALS3为靶点进行虚拟筛选,开发抗白念珠菌生物膜苗头化合物具有可行性;揭示PAC为白念珠菌ALS3靶点抑制剂,其抗生物膜机制与能量代谢、核酸合成障碍、膜结构破坏以及氧化应激加剧相关。.
引用
- Ding WJ, Zhou AQ, Qu W, et al. [Integrated analysis of molecular docking and metabolomics on the anti-candida albicans biofilm mechanism of proanthocyanidins]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42595545. doi:10.3760/cma.j.cn112150-20250814-00793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。